Handbook Of Tuberculosis

This concise, clinically focused handbook offers a complete overview of tuberculosis and reviews the latest guidelines, treatment options, clinical trials and management of this disease. Handbook of Tuberculosis is a well-rounded book written by renowned researchers at the Johns Hopkins Center for Tuberculosis Research. The easily accessible text offers infectious disease specialists, pulmonologists, and other healthcare workers an excellent quick reference tool, with full color tables and figures enhancing the text further. Tuberculosis is a life-threatening lung infection that affects people of all ages. It is the second biggest cause of death from infectious diseases and is the most common cause of death amongst patients with HIV/AIDS. Education on the recognition of tuberculosis and the subsequent treatment of the disease is empirical to the prevention of wide-spread resistance. There is a lack of knowledge on how to treat coinfected and comorbid patients, this handbook offers the latest medical guidance and treatment options to equip physicians to manage such patients.

The WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease is an updated and consolidated summary of WHO recommendations on systematic screening for tuberculosis (TB) disease, containing 17 recommendations for populations in which TB screening should be conducted and tools to be used for TB screening. TB screening is strongly recommendations for household and close contacts of individuals with TB, people living with HIV, miners exposed to silica dust, and prisoners. In addition, screening is conditionally recommended for people with risk factors for TB attending health care, and for communities with risk factors for TB and limited access to care (e.g. homeless, urban poor, refugees, migrants). General population screening is recommended in high-burden settings (0.5% prevalence or higher). Symptoms, chest radiography (CXR), and molecular WHO-recommended rapid diagnostic tests for TB are recommended as screening tools for all adults eligible for screening. Computer-aided detection programmes are recommended as alternatives to human interpretation of CXR in settings where trained personnel are scarce. For people living with HIV, C-reactive protein is also a good screening tool. This guideline document is accompanied by an operational handbook, the WHO operational handbook on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease, that presents principles of screening, steps in planning and implementing a screening programme, and algorithm options for screening different populations.

This ambitious reference surveys worldwide efforts at controlling the spread of tuberculosis, with special emphasis on the developing world. Case studies from China, Pakistan, Nigeria, Indonesia, and other frontline countries demonstrate a wealth of information on clinical, cultural, socioeconomic, and other relevant factors. This compilation provides a valuable resource for creating successful intervention and prevention strategies. State-of-the-science snapshots pinpoint where short- and long-term initiatives stand today, from early detection and vaccination programs to new genetic technologies and drug therapies. This diverse group of perspectives and approaches offers innovative paths toward control and realistic odds for containing the threat, especially in the face of current co-epidemics and new drug-resistant strains. Among the topics in the Handbook: Diagnosis of tuberculosis: current pipeline, unmet needs, and new developments Concurrence of tuberculosis and other major diseases The tuberculosis outbreak response, investigation, and control The promise of new TB vaccines DNA fingerprinting of Mycobacterium tuberculosis: a rich source of fundamental and daily applicable knowledge Global tuberculosis surveillance The Handbook of Global Tuberculosis Control is urgent reading for leadership and staff of non-governmental organizations, government agencies, academic institutions, research centers, hospitals, and potentially businesses with interests in tuberculosis control. Additionally, the book's focus on TB in developing countries will attract a wider audience of practitioners, particularly those working in the broader fields of global public health, epidemiology, international development, and the socioeconomics of infectious diseases.

Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community.

Tuberculosis remains one of the most prevalent, deadly, and underdiagnosed infectious diseases in the world. In children, this burden is doubly problematic because of the disease's unique clinical characteristics and its need for special public health and diagnostic techniques. After decades of relative inattention to these factors, childhood tuberculosis has now grown into an important area of competency for child health programs in low-burden areas, including the United States. The Handbook of Child and Adolescent Tuberculosis is a state of the art clinical reference written and edited by the world's leading experts in childhood tuberculosis. It offers clinicians in any geography or setting practical, evidence-based advice on all aspects of the disease, including its natural history, epidemiology, presentation, treatment, and prevention -- all in a format that synthesizes literature with the clinical experience of the leading authorities in this challenging field. As the need for childhood tuberculosis services in child health programs grows, this handbook provides a new benchmark for practitioners and trainees in pediatrics, infectious disease, pulmonary medicine, and public health to better understand this persisting and difficult disease.

This second of the three-volume tuberculosis book series provides a comprehensive overview of clinical, diagnostic, therapeutic, and epidemiological aspects of tuberculosis. Edited by the undisputed world leader in the field, this is the most comprehensive book on the topic available, and the first in recent years to focus on both basic research and clinical aspects of TB.

Rev. ed. of: Assessing tuberculosis prevalence through population-based surveys. 2007.

This concise, clinically focused handbook offers a complete overview of tuberculosis and reviews the latest guidelines, treatment options, clinical trials and management of this disease. Handbook of Tuberculosis is a well-rounded book written by renowned researchers at the Johns Hopkins Center for Tuberculosis Research. The easily accessible text offers infectious disease specialists, pulmonologists, and other healthcare workers an excellent quick reference tool, with full color tables and figures enhancing the text further. Tuberculosis is a life-threatening lung infection that affects people of all ages. It is the second biggest cause of death from infectious diseases and is the most common cause of death amongst patients with HIV/AIDS. Education on the recognition of tuberculosis and the subsequent treatment of the disease is empirical to the prevention of wide-spread resistance. There is a lack of knowledge on how to treat coinfected and comorbid patients, this handbook offers the latest medical guidance and treatment options to equip physicians to manage such patients.

Coinciding with the first TB therapies to enter clinical trials in 60 years, this is the most comprehensive account of the latest developments in clinical, therapeutic and basic research into the disease, presented by the most prolific of all researchers in the field. Divided into three clearly structured volumes, the first deals with molecular biology and biochemistry of the pathogen, including genetics and genomics, as well as drug design. The second volume covers cell biology, immunology and vaccine development, while the third is devoted to epidemiology and clinical approaches, including drug resistance, veterinary aspects and clinical field trials. With one new infection worldwide every second, this is an essential reference for bacteriologists, immunologists, pathologists and pathophysiologists, molecular and cell biologists, as well as those working in the pharmaceutical industry.

The political declaration of the first United Nations (UN) high-level meeting on tuberculosis (TB) calls countries to diagnose and treat 40 million people with TB globally between 2018 and 2022. Traditionally, in most countries, TB diagnosis has been performed using sputum-smear microscopy, a method developed more than 100 years ago, with suboptimal sensitivity. In recent years new technologies have emerged based on the detection of mycobacterial DNA or mycobacterial antigens. Over the past decade the World Health Organization (WHO) has published a number of guidelines developed by WHO-convened Guideline Development Groups (GDGs), using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to summarize the evidence and to formulate policy recommendations and accompanying remarks. The present document "WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection" consolidates five guidelines developed by WHO between 2016 and 2020. Earlier guidelines on diagnostics that were not developed according to the GRADE approach have not been included in this document. The WHO Consolidated Guidelines on Tuberculosis will group all TB recommendations in one document and will be complemented by matching modules of an operational handbook. The handbook will provide practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact. A range of new diagnostic technologies have been endorsed by WHO during the past decade. These are listed below: - real-time polymerase chain reaction (PCR) assays - for example, Xpert MTB/RIF(r) (Ultra) (cartridge-based) and TruenatTM (chip-based);- line probe assays (LPAs) - for example, GenoType(r) MTBDRplus v1 and v2, GenoscholarTM NTM+MDRTB II and GenoType(r) MTBDRsl;- loop-mediated isothermal amplification (LAMP) - for example, TB-LAMP; and- antigen detection in a lateral flow format (biomarker-based detection) - for example, Alere DetermineTM TB LAM Ag. The present "WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection" provides background, justification and recommendations on these technologies. The document includes new recommendations on molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children.